Visit our CLL Information and Resource CentreA guide for patients looking for answers to their CLL questions on the Internet. |
A new Canadian website is making it easier for cancer patients to explore clinical trial options. Search for trials across Canada using simple keywords and filters or get help navigating the site through the Canadian Cancer Society’s Cancer Information Helpline.
In late 2025, the American Society of Hematology (ASH) conference highlighted many important updates for people living with Chronic Lymphocytic Leukemia (CLL), including emerging treatment approaches, long-term follow-up on existing therapies.
Calling all patients and care partners to share their experiences to improve patient outcomes. The 2026 Global Patient Survey on Lymphoma & CLL (GPS) is the only opportunity for the worldwide lymphoma and CLL community of patients and care partners to share insights…
Pirtobrutinib (brand name Jaypirca) has been approved by Health Canada and is available for use as monotherapy for the treatment of adult patients in Canada with CLL/SLL who have received at least two prior lines of therapy…
Richter transformation (RT) is a rare but serious change that can happen in people with chronic lymphocytic leukemia (CLL), where the slower-growing CLL becomes a more aggressive form of lymphoma.
Combination treatments using drugs that target different CLL mechanisms have shown promising results for patients in clinical trials. And the great news is that some treatments that combine BTK and BCL2 inhibitors are now being approved as first line treatment options in Canada.
Understanding your preferred communication style can significantly enhance your relationship with your healthcare team and empower you to make informed decisions about your health.
The development of a new cancer drug at the University of Alberta shows both the promise and the challenges of drug development.
There is some good news to share on the treatment front! Since spring 2025, six provinces in Canada have made publicly funded Ibrutinib + Venetoclax (I+V) combination therapy available for previously untreated CLL patients.
Over a ten-year span, the treatment landscape for chronic lymphocytic leukemia (CLL) has improved dramatically.
